
Bright Minds Biosciences Inc. announced on January 6, 2026, that it had launched a public offering targeting aggregate gross proceeds of US$100 million. The biotechnology company intends to use the net proceeds to support clinical trials. Additionally, it will support earlier-stage research and general corporate and working capital needs.
The proposed offering includes common shares. For investors who choose them instead of common shares, pre-funded warrants to purchase common shares are also included. Bright Minds trades on the Canadian Securities Exchange and Nasdaq under the symbol DRUG.
Proceeds Intended for Clinical Trials and Research
Bright Minds plans to use the net proceeds to fund future clinical trials for its drug candidates. These trials include those for absence seizures, DEE, and Prader-Willi syndrome.
The planned uses also include initiating Phase 1 clinical trials for BMB-105. In addition, the company will conduct more research and development on earlier-stage programs. It will also support general corporate and working capital requirements.
Four Firms Managing the Offering
Jefferies, TD Cowen, Piper Sandler & Co., and Cantor are acting as joint book-running managers for the proposed offering.
Bright Minds also intends to grant the underwriters a 30-day option. This allows them to purchase up to an additional 15% of the common shares issued in the offering.
Offering Uses Existing Shelf Registration
The securities are being offered under a shelf registration statement on Form F-3 that the U.S. Securities and Exchange Commission declared effective on September 2, 2025. The offering is being made solely through a prospectus and prospectus supplement forming part of that registration statement.
Bright Minds said a preliminary prospectus supplement and accompanying prospectus would be filed with the SEC. It advised investors to read those documents and its other SEC filings for information about the company and the offering.
The January 6 announcement does not establish that the financing was completed. Bright Minds identified completion of the proposed offering and its expected use of proceeds as forward-looking matters. These are subject to risks and uncertainties.
About Bright Minds Biosciences
Bright Minds Biosciences develops potential treatments for neurological and psychiatric disorders. Its pipeline includes novel compounds targeting key receptors in the brain. The focus is on conditions with high unmet medical need, including epilepsy, depression, and other central nervous system disorders.
The company has developed a platform of highly selective serotonergic agonists targeting different serotonin receptors. This platform supports its portfolio of new chemical entity programs in neurology and psychiatry.
Contact Information
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: [email protected]
Website: www.brightmindsbio.com

